Cargando…

The experience of pain and redness in patients with moderate to severe plaque psoriasis

Introduction: The Psoriasis Symptom Inventory is a patient-reported outcome instrument that assesses severity of psoriasis signs and symptoms. In early qualitative research, patients reported pain related to psoriasis skin lesions and redness of affected areas of skin as key symptoms. Methods: Indiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Mona L., Gordon, Kenneth, Pinto, Lionel, Bushnell, Donald M., Chau, Dina, Viswanathan, Hema N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2015
Materias:	Psoriasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743609/ https://www.ncbi.nlm.nih.gov/pubmed/25822169 http://dx.doi.org/10.3109/09546634.2014.996514

Ejemplares similares

Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response
por: Sawyer, L.M., et al.
Publicado: (2018)

Quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study
por: van de Kerkhof, P.C.M., et al.
Publicado: (2019)

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis
por: Gooderham, M., et al.
Publicado: (2022)

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study
por: Valenzuela, F., et al.
Publicado: (2016)

Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate‐to‐severe genital psoriasis
por: Merola, J.F., et al.
Publicado: (2020)

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
por: Blauvelt, A., et al.
Publicado: (2018)

Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study
por: Cai, L., et al.
Publicado: (2016)

First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis
por: Kaul, M., et al.
Publicado: (2021)

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
por: Strober, B., et al.
Publicado: (2020)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
por: Reich, K., et al.
Publicado: (2016)

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO study
por: Richard, M.‐A., et al.
Publicado: (2020)

Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology
por: Arnone, Marcelo, et al.
Publicado: (2019)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)
por: Seneschal, J., et al.
Publicado: (2020)

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)
por: Callis Duffin, K., et al.
Publicado: (2016)

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)
por: Bagel, J., et al.
Publicado: (2020)

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
por: Papp, K.A., et al.
Publicado: (2018)

Non‐invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator‐initiated, phase IV, unicentric, open, randomized clinical trial
por: Yélamos, O., et al.
Publicado: (2020)

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials
por: Blauvelt, A., et al.
Publicado: (2019)

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study
por: Lebwohl, M.G., et al.
Publicado: (2019)

Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
por: Warren, R. B., et al.
Publicado: (2021)

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
por: Bissonnette, R., et al.
Publicado: (2018)

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials
por: Thaçi, D., et al.
Publicado: (2016)

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial
por: Bodemer, C., et al.
Publicado: (2021)

Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials
por: Hampton, P., et al.
Publicado: (2021)

Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching‐adjusted indirect comparison
por: Bewley, A.P., et al.
Publicado: (2019)

Image‐based automated Psoriasis Area Severity Index scoring by Convolutional Neural Networks
por: Schaap, M.J., et al.
Publicado: (2021)

Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab
por: Umezawa, Y., et al.
Publicado: (2018)

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
por: Mrowietz, U., et al.
Publicado: (2021)

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry
por: Mease, P.J., et al.
Publicado: (2019)

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)
por: Tveit, K.S., et al.
Publicado: (2018)

An Atlas of psoriasis
por: Fry, Lionel
Publicado: (1992)

Safety and efficacy of fixed‐dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open‐label trial
por: Seyger, M., et al.
Publicado: (2020)

Fumaric acid ester‐induced T‐cell lymphopenia in the real‐life treatment of psoriasis
por: Dickel, H., et al.
Publicado: (2019)

Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians
por: van Ee, I., et al.
Publicado: (2021)

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
por: Rungapiromnan, W., et al.
Publicado: (2019)

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom
por: Warren, R.B., et al.
Publicado: (2018)

Long‐term real‐life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single‐centre, retrospective, observational study
por: Dickel, H., et al.
Publicado: (2018)

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study
por: Paul, C., et al.
Publicado: (2016)

Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J)
por: Okubo, Y., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l31ad891e4tr9qdshv5dkk4ke9